In many ways, 2024 was a year of consolidation at the top of the pharma industry rankings. Johnson & Johnson, having ascended to the top spot in 2023 held on to that position in 2024, adding more than US$2.2 billion in year-on-year sales growth to hit $55.7 billion for the year (Fig. 1a). Darzalex (daratumumab), an anti-CD38 monoclonal antibody (mAb) for multiple myeloma, continues to be the biggest single growth driver for the company.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The author declares no competing interests.
